Companies in #GLP-1 and Dual Agonists
Found 1 company operating in this sector.
Gan & Lee Pharmaceuticals is a Chinese biopharmaceutical company specializing in insulin analogs and biosimilar peptides, with a leading share of China's domestic insulin market. In addition to its diabetes franchise, the company has expanded into metabolic disease and obesity with next-generation GLP-1 / dual-agonist programs. In June 2026, Gan & Lee reported positive Phase 3 results for its obesity peptide candidate and is preparing to expand outside of China through partnerships and licensing deals.